Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1438 participants.

Also called NCT01785472

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,438 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01785472
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Hong Kong SAR China, Philippines, Singapore, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01785472. Randomized; double masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-09-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Olmesartan
Intervention (Drug)
Placebo of LCZ696
Intervention (Drug)
Placebo of Olmesartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01785472
Content hash
d94893ab9977fb854177b0c9716d9d179e03ab08e39178485bc7c8470106568a